Pharmacoeconomics: From Theory to PracticeRenee J. G. Arnold The pharmaceutical industry is almost boundless in its ability to supply new drug therapies, but how does one decide which are the best medicines to use within restricted budgets? With particular emphasis on modeling, methodologies, data sources, and application to real-world dilemmas, Pharmacoeconomics: From Theory to Practice provides an introduc |
Contents
Chapter 1 Introduction to Pharmacoeconomics | 1 |
Chapter 2 Decision Modeling Techniques | 17 |
Chapter 3 Cost of Illness | 37 |
Chapter 4 Markov Modeling in Decision Analysis | 47 |
Chapter 5 Retrospective Database Analysis | 59 |
Chapter 6 What Is Cost Minimization Analysis? | 83 |
Chapter 7 CostEffectiveness Analysis | 95 |
Chapter 8 Budget Impact Analysis | 109 |
Chapter 11 PatientReported Outcome Measures | 149 |
Chapter 12 Sensitivity Analysis | 163 |
What Can We Learn from International Experience? | 175 |
Practical Applications and Persistent Challenges | 197 |
Chapter 15 ComputerAided Decision Making from Drug Discovery to Pharmacoeconomics | 209 |
Chapter 16 Speculations on the Future Challenges and Value of Pharmacoeconomics | 227 |
| 237 | |
Back cover | 244 |
A Case Study of a Quadrivalent Human Papillomavirus Vaccine | 119 |
Chapter 10 Some Problems Assumptions in Pharmacoeconomic Analysis | 133 |
Other editions - View all
Common terms and phrases
acceptable addition alternative analysis applied approach appropriate assessment associated assumed benefits budget calculated cervical cervical cancer Chapter choice claims clinical compared condition considered cost-effectiveness costs databases decision decision-making detailed determine discount disease DM programs drug economic effectiveness equivalence estimate evaluation evidence example existing expected Figure function future gained given guidelines healthcare hospital HPV vaccine human impact important improve increased incremental individual interest interventions issues limited Markov measure Medicine methods options outcomes parameters particular patients perspective pharmaceutical pharmacoeconomic population possible potential practice present probability problem programs Progressive QALY range ratio reference represent resource risk screening shows sources specific step strategy structure Table testing therapy tion treatment trials types United utility vaccine validity variables